VYGR

Over the past six months, Voyager Therapeutics' stock has been influenced by financial results, pipeline advancements, and analyst activities. Voyager reported its First Quarter 2026 financial results, including collaboration revenue of $2.6 million and a net loss of $27.9 million. Voyager's IV-delivered CNS gene therapies were featured in multiple presentations at ASGCT 2026. The company held a "BBBreaking BBBarriers: TRACER Platform Deep Dive" event. An analyst report maintained a "Strong Buy" rating. Voyager participated in a "BBBreaking BBBarriers: A NeuroShuttle Deep Dive" event and the Stifel 2026 Virtual CNS Forum. Voyager reported its Fourth Quarter and Full Year 2025 financial results, with a quarterly loss of $27.4 million and revenue of $15.3 million. Voyager presented at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. Voyager participated in the Stifel 2025 Healthcare Conference and reported Q3 2025 earnings with a loss of -$0.470 USD per share. The stock price as of May 1, 2026, was $3.75, with analysts having a median target of $22.00.